What is the clinical evidence from this study?

Study design: Other. Intervention: Remikiren vs. Baseline and AT1-receptor antagonist L-158,809. Primary outcome: Haemodynamics and regional myocardial function (MAP, CO, HR, SVR, MVO2, LV dP/dtmax) (p=<0.05).

What does this research mean for the field?

High-dose systemic and intracoronary infusion of the renin inhibitor remikiren in pigs significantly decreases left ventricular contractility, supporting the hypothesis that myocardial contractility is increased by local renin-dependent angiotensin II formation in the heart. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to evaluate how renin inhibition influences myocardial contractility and its dependency on intracardiac angiotensin II levels.

March 1, 1996British Journal of PharmacologyOpen Access

Assessment of the role of the renin‐angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren

Q: What are the key findings of this study?

High-dose systemic and intracoronary infusion of remikiren in pigs decreased left ventricular dP/dtmax by 52% and 43% respectively (P<0.05), supporting local renin-dependent angiotensin II formation.

Q: What does this research mean for the field?

High-dose systemic and intracoronary infusion of the renin inhibitor remikiren in pigs significantly decreases left ventricular contractility, supporting the hypothesis that myocardial contractility is increased by local renin-dependent angiotensin II formation in the heart. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

This research aims to evaluate how renin inhibition influences myocardial contractility and its dependency on intracardiac angiotensin II levels.

View Full Paper

Ask AI

Bookmark

Key result

High-dose systemic and intracoronary infusion of remikiren in pigs decreased left ventricular dP/dtmax by 52% and 43% respectively (P<0.05), supporting local renin-dependent angiotensin II formation.

Population

Open-chest anaesthetized pigs (25-30 kg) and porcine isolated cardiac trabeculae

Comparison

Systemic and intracoronary infusions of the… vs Baseline measurements prior to infusion

Design

Preclinical

Follow-up

10 minutes per infusion

Authors

JKJorge P. van KatsErasmus MC LSL.M.A. SassenErasmus University Rotterdam ADA.H. Jan DanserVascular Medicine

Discussion

Member takes

Implication

Animal data link local cardiac angiotensin II to contractility; leaves open translation to human ventricular function or therapy.

Key Points

This research aims to evaluate how renin inhibition influences myocardial contractility and its dependency on intracardiac angiotensin II levels.
Utilized open-chest anaesthetized pigs (25-30 kg) for experiments.
Administered systemic (i.v.) and intracoronary (i.c.) infusions of remikiren at varying doses for effect comparison.
Measured hemodynamic parameters including MAP, CO, heart rate (HR), and myocardial oxygen consumption (MVO2) during interventions.
At the highest i.v. dose, MAP decreased by 48%, CO by 13%, HR by 14%, and LV dP/dtmax by 52% (P < 0.05).
Intracoronary remikiren at the max dose resulted in a MAP decrease of 31% and LV dP/dtmax decrease of 43% (P < 0.05).
Effects of remikiren were reduced after AT1-receptor blockade, indicating partial dependence on intracardiac angiotensin II.

Structured PICO

Population

Open-chest anaesthetized pigs (25-30 kg) and porcine isolated cardiac trabeculae

Intervention

Systemic (i.v.) and intracoronary (i.c.) infusions of the renin inhibitor remikiren (i.v. at 2, 5, 10 and 20 mg min-1; i.c. at 0.2, 0.5, 1, 2, 5 and 10 mg min-1 for 10 min each)

Comparator

Baseline measurements prior to infusion

Outcome

Systemic haemodynamics (MAP, CO, HR, SVR), myocardial oxygen consumption (MVO2), and left ventricular (LV) dP/dtmaxsurrogate

Main Result

p-value: p=<0.05

Remikiren lowers blood pressure primarily by vasodilation when given i.v., and by cardiac depression when given i.c., supporting the concept that myocardial contractility is increased by renin-dependent angiotensin II formation in the heart.

Cite This Study

Kats et al. (1996) studied this question. Remikiren vs. Baseline and AT1-receptor antagonist L-158,809 was evaluated on Haemodynamics and regional myocardial function (MAP, CO, HR, SVR, MVO2, LV dP/dtmax) (p=<0.05). High-dose systemic and intracoronary infusion of remikiren in pigs decreased left ventricular dP/dtmax by 52% and 43% respectively (P<0.05), supporting local renin-dependent angiotensin II formation.

synapsesocial.com/papers/6a15984779ff98d0de4edce2 https://doi.org/10.1111/j.1476-5381.1996.tb15277.x

View Full Paper

Ask AI

Bookmark

Assessment of the role of the renin‐angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Assessment of the role of the renin‐angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider